Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation (2014) 3.28

Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02

Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol (2010) 1.27

Inter-subject variability in human atrial action potential in sinus rhythm versus chronic atrial fibrillation. PLoS One (2014) 0.98

Na/K pump regulation of cardiac repolarization: insights from a systems biology approach. Pflugers Arch (2013) 0.95

Dronedarone-digoxin interaction in PALLAS: A foxglove connection? Glob Cardiol Sci Pract (2015) 0.95

Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacol Ther (2011) 0.94

The Na+/K+ pump is an important modulator of refractoriness and rotor dynamics in human atrial tissue. Am J Physiol Heart Circ Physiol (2011) 0.94

Dronedarone. Nat Rev Drug Discov (2009) 0.93

Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol (2011) 0.93

Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther (2011) 0.89

Atrial fibrillation: Dronedarone and amiodarone-the safety versus efficacy debate. Nat Rev Cardiol (2010) 0.86

Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm (2010) 0.84

Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther (2011) 0.83

Addressing the management of atrial fibrillation - a systematic review of the role of dronedarone. Int J Gen Med (2012) 0.82

Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. Clin Interv Aging (2010) 0.81

Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. Vasc Health Risk Manag (2010) 0.81

Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm (2012) 0.80

Acute effects of intravenous dronedarone on electrocardiograms, hemodynamics and cardiac functions in anesthetized dogs. J Vet Med Sci (2015) 0.79

Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. Eur J Clin Pharmacol (2012) 0.78

Early management of atrial fibrillation: from imaging to drugs to ablation. Nat Rev Cardiol (2010) 0.78

Pharmacologic management of arrhythmias. Tex Heart Inst J (2011) 0.78

Antiarrhythmic therapy in atrial fibrillation: indications, guidelines, and safety. Tex Heart Inst J (2012) 0.77

Cost considerations in the management of atrial fibrillation - impact of dronedarone. Clinicoecon Outcomes Res (2012) 0.77

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone. Clin Interv Aging (2011) 0.75

Advances in the Pharmacological Treatment of Atrial Fibrillation. Curr Med Lit Cardiol (2010) 0.75

Amiodarone or dronedarone for atrial fibrillation: too early to know the winner? J Am Coll Cardiol (2009) 0.75

Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedarone. Patient Relat Outcome Meas (2012) 0.75

Dronedarone is superior to placebo the case for optimism. J Am Coll Cardiol (2010) 0.75

[Not Available]. Med Klin (Munich) (2010) 0.75

Management of atrial fibrillation: focus on the role of dronedarone. Open Access Emerg Med (2011) 0.75

Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes. J Gen Intern Med (2010) 0.75

The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. Eur Heart J Cardiovasc Pharmacother (2015) 0.75

Dronedarone in patients with atrial fibrillation. Neth Heart J (2010) 0.75

Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation. Core Evid (2010) 0.75

Current issues in atrial fibrillation. ISRN Cardiol (2012) 0.75

How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era? Curr Cardiol Rev (2015) 0.75

Is dronedarone really safer than amiodarone? Indian J Pharmacol (2012) 0.75

Atrial fibrillation. J Biomed Res (2013) 0.75

[New developments in the antiarrhythmic therapy of atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2010) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90

Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA (2009) 13.69

Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol (2007) 10.19

The ClinicalTrials.gov results database--update and key issues. N Engl J Med (2011) 9.83

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70

Low diagnostic yield of elective coronary angiography. N Engl J Med (2010) 9.38

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28

Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22

Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med (2013) 8.08

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78

ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol (2006) 7.77

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ (2002) 6.98

Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA (2010) 6.91

Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation (2007) 6.78

2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2009) 6.61

Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA (2005) 6.10

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA (2005) 5.93

Comparative effectiveness of revascularization strategies. N Engl J Med (2012) 5.49

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 5.05

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04

Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA (2007) 4.89

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2009) 4.75

Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation (2011) 4.65

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol (2002) 4.64

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57

What clinicians should know about the QT interval. JAMA (2003) 4.45

Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42

The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. Ann Thorac Surg (2009) 4.39

Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38

Compliance with results reporting at ClinicalTrials.gov. N Engl J Med (2015) 4.17

Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA (2010) 4.13

Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2006) 4.11

An empirically based tool for analyzing mortality associated with congenital heart surgery. J Thorac Cardiovasc Surg (2009) 4.10

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA (2008) 4.06

Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97

Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation (2006) 3.96

Improving patient care. The patient centered medical home. A Systematic Review. Ann Intern Med (2012) 3.90

Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. Eur J Cardiothorac Surg (2002) 3.86

Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83

ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation (2002) 3.80

Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79

Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med (2002) 3.77

Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72

Conversion of cardiovascular conference abstracts to publications. Circulation (2012) 3.71

Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA (2011) 3.68

Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA (2012) 3.66

Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62

An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 3.60

Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58

Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57

Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA (2005) 3.51

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45

Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA (2004) 3.45

The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2--isolated valve surgery. Ann Thorac Surg (2009) 3.45

Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA (2011) 3.44

Effect of clinical decision-support systems: a systematic review. Ann Intern Med (2012) 3.42

Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation. Circulation (2005) 3.38

Benefits of smoking cessation for longevity. Am J Public Health (2002) 3.38

Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. Circulation (2006) 3.38

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol (2011) 3.37

Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol (2008) 3.35

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008) 3.34

Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation (2011) 3.30

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 3.24

Association between physician billing and cardiac stress testing patterns following coronary revascularization. JAMA (2011) 3.19

Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA (2012) 3.07

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer (2002) 3.05

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J (2008) 3.02

Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01